275 related articles for article (PubMed ID: 33288483)
1. Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.
Chihara D; Dunleavy K
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):73-79. PubMed ID: 33288483
[TBL] [Abstract][Full Text] [Related]
2. Immune and Cell Therapy in Non-Hodgkin Lymphoma.
Merryman RW; Houot R; Armand P; Jacobson C
Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460
[TBL] [Abstract][Full Text] [Related]
3. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
Nagane M
Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
[TBL] [Abstract][Full Text] [Related]
4. Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.
Tateishi K; Miyake Y; Nakamura T; Yamamoto T
Brain Tumor Pathol; 2021 Jul; 38(3):173-182. PubMed ID: 34255226
[TBL] [Abstract][Full Text] [Related]
5. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
[TBL] [Abstract][Full Text] [Related]
6. Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.
Zou R; Zhou X; Liu H; Wang P; Xia F; Kang L; Yu L; Wu D; Jin Z; Qu C
Cancer Res Treat; 2023 Oct; 55(4):1363-1368. PubMed ID: 37321275
[TBL] [Abstract][Full Text] [Related]
7. Central Nervous System Lymphoma: Approach to Diagnosis and Treatment.
Correia CE; Schaff LR; Grommes C
Cancer J; 2020; 26(3):241-252. PubMed ID: 32496457
[TBL] [Abstract][Full Text] [Related]
8. [New treatment strategies for primary lymphoma of the central nervous system].
Seidel S; Kaulen L; von Baumgarten L
Nervenarzt; 2024 Feb; 95(2):117-124. PubMed ID: 37910181
[TBL] [Abstract][Full Text] [Related]
9. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma.
Roschewski M; Phelan JD; Wilson WH
Cancer J; 2020; 26(3):195-205. PubMed ID: 32496453
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
[TBL] [Abstract][Full Text] [Related]
11. New approaches in primary central nervous system lymphoma.
Fraser E; Gruenberg K; Rubenstein JL
Chin Clin Oncol; 2015 Mar; 4(1):11. PubMed ID: 25841718
[TBL] [Abstract][Full Text] [Related]
12. Challenges in the management of primary central nervous system lymphoma.
Sun X; Lv L; Wu Y; Cui Q; Sun S; Ji N; Liu Y
Crit Rev Oncol Hematol; 2023 Aug; 188():104042. PubMed ID: 37277008
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).
Liu Y; Yao Q; Zhang F
Int J Oncol; 2021 Mar; 58(3):371-387. PubMed ID: 33650642
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic options for relapsed/refractory mantle cell lymphoma.
Eyre TA; Cheah CY; Wang ML
Blood; 2022 Feb; 139(5):666-677. PubMed ID: 34679161
[TBL] [Abstract][Full Text] [Related]
15. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
Fritsch K; Kasenda B; Hader C; Nikkhah G; Prinz M; Haug V; Haug S; Ihorst G; Finke J; Illerhaus G
Ann Oncol; 2011 Sep; 22(9):2080-2085. PubMed ID: 21303800
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
[TBL] [Abstract][Full Text] [Related]
17. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
[TBL] [Abstract][Full Text] [Related]
18. Evolving Treatments for Primary Central Nervous System Lymphoma.
Ferreri AJM; Holdhoff M; Nayak L; Rubenstein JL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():454-466. PubMed ID: 31099614
[TBL] [Abstract][Full Text] [Related]
19. What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
McCulloch R; Eyre TA; Rule S
Hematol Oncol Clin North Am; 2020 Oct; 34(5):923-939. PubMed ID: 32861287
[TBL] [Abstract][Full Text] [Related]
20. Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Illerhaus G; Schorb E; Kasenda B
Blood; 2018 Aug; 132(7):681-688. PubMed ID: 29986908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
